Drug Trial Radar · NCT07019922
A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety
Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Aug 13, 2025
Primary completion
Dec 2026
Study completion Dec 2028
Sponsor
- Lead sponsor
- Praxis Precision MedicinesIndustry
- Sponsor type
- Industry
- First posted
- Jun 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 day, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Multi-Center, Single-Arm Clinical Trial to Investigate the Efficacy and Safety of Elsunersen in Pediatric Participants with Early Onset SCN2A Developmental and Epileptic Encephalopathy
Conditions
- Epileptic Encephalopathy
- SCN2A Encephalopathy
Interventions
1mg elsunersenDrug
24 weeks every 4 weeks intrathecally
0.5mg elsunersenDrug
24 weeks every 4 weeks intrathecally
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the efficacy of elsunersen on seizure frequency in participants with early-onset SCN2A DEETime frame: 24 weeks
Locations
10 sites in 4 countries. Site status is shown where the registry gives one.
Praxis Research Site
San Diego, California · Recruiting
Praxis Research Site
Aurora, Colorado · Recruiting
Praxis Research Site
Chicago, Illinois · Recruiting
Praxis Research Site
Cincinnati, Ohio · Recruiting
Praxis Research Site
Philadelphia, Pennsylvania · Recruiting
Praxis Research Site
Memphis, Tennessee · Recruiting
Praxis Research Site
Porto Alegre, Brazil · Withdrawn
Praxis Research Site
São Paulo, Brazil · Withdrawn
Praxis Research Site
Bonn, Bonn, Germany · Recruiting
Praxis Research Site
Rome, Italy · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.